Mesna	B-disease	B-disease
'	O	O
s	O	O
action	O	O
,	O	O
in	O	O
conjunction	O	O
with	O	O
IFO	B-disease	B-disease
reduces	O	O
the	O	O
frequency	O	O
of	O	O
SCEs	O	O
,	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
SCEs	O	O
recordings	O	O
obtained	O	O
when	O	O
IFO	B-disease	B-disease
is	O	O
administered	O	O
alone	O	O
.	O	O
Newly	O	O
identified	O	O
links	O	O
to	O	O
kidney	O	B-disease
cancer	O	I-disease
and	O	O
associations	O	O
with	O	O
aggressive	O	O
prostate	O	B-disease
cancer	O	I-disease
require	O	O
further	O	O
evaluation	O	O
.	O	O
The	O	O
hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B-disease	B-disease
,	O	O
a	O	O
noniodinated	O	O
compound	O	O
structurally	O	O
related	O	O
to	O	O
amiodarone	B-disease	B-disease
,	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
amiodarone	B-disease	B-disease
after	O	O
prolonged	O	O
oral	O	O
administration	O	O
,	O	O
both	O	O
at	O	O
rest	O	O
and	O	O
during	O	O
sympathetic	O	O
stimulation	O	O
in	O	O
conscious	O	O
dogs	O	O
with	O	O
a	O	O
healed	O	O
myocardial	O	O
infarction	O	O
.	O	O
Plasma	O	O
ammonium	B-disease	B-disease
level	O	O
ranged	O	O
from	O	O
248	O	O
to	O	O
2387	O	O
microg	O	O
%	O	O
(	O	O
mean	O	O
:	O	O
626	O	O
+	O	O
/	O	O
-	O	O
431	O	O
microg	O	O
%	O	O
)	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
maximum	O	O
antihyperalgesic	O	O
effect	O	O
achievable	O	O
with	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B-disease	B-disease
may	O	O
be	O	O
increased	O	O
significantly	O	O
when	O	O
the	O	O
drug	O	O
is	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
CNSB002	B-disease	B-disease
.	O	O
The	O	O
rate	O	O
of	O	O
NA	B-disease	B-disease
turnover	O	O
was	O	O
not	O	O
altered	O	O
by	O	O
analgesics	O	O
except	O	O
for	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
fentanyl	B-disease	B-disease
(	O	O
0	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
following	O	O
which	O	O
the	O	O
disappearance	O	O
of	O	O
NA	B-disease	B-disease
from	O	O
the	O	O
brain	O	O
was	O	O
diminished	O	O
.	O	O
The	O	O
risk	O	O
of	O	O
VNR	B-disease	B-disease
cardiac	O	O
events	O	O
was	O	O
similar	O	O
to	O	O
vindesine	B-disease	B-disease
(	O	O
VDS	B-disease	O
)	O	O
and	O	O
other	O	O
cardiotoxic	O	O
drugs	O	O
[	O	O
fluorouracil	B-disease	B-disease
,	O	O
anthracyclines	B-disease	B-disease
,	O	O
gemcitabine	B-disease	B-disease
(	O	O
GEM	B-disease	O
)	O	O
em	O	O
leader	O	O
]	O	O
.	O	O
The	O	O
findings	O	O
indicate	O	O
that	O	O
thalidomide	B-disease	B-disease
may	O	O
be	O	O
an	O	O
option	O	O
for	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
other	O	O
forms	O	O
of	O	O
therapy	O	O
,	O	O
provided	O	O
close	O	O
follow	O	O
-	O	O
up	O	O
is	O	O
maintained	O	O
for	O	O
development	O	O
of	O	O
peripheral	O	O
neuropathy	O	O
.	O	O
To	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
fatal	O	O
carbamazepine	B-disease	B-disease
induced	O	O
myocarditis	O	O
reported	O	O
in	O	O
English	O	O
literature	O	O
.	O	O
The	O	O
effects	O	O
of	O	O
i	O	O
.	O	O
v	O	O
.	O	O
bolus	O	O
administration	O	O
of	O	O
cromakalim	B-disease	B-disease
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pinacidil	B-disease	B-disease
(	O	O
3	O	O
-	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
large	O	O
(	O	O
circumflex	O	O
artery	O	O
)	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
on	O	O
systemic	O	O
hemodynamics	O	O
were	O	O
investigated	O	O
in	O	O
chronically	O	O
instrumented	O	O
conscious	O	O
dogs	O	O
and	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
nitroglycerin	B-disease	B-disease
(	O	O
0	O	O
.	O	O
03	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
.	O	O
Our	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
provision	O	O
of	O	O
alcohol	B-disease	B-disease
use	O	O
interventions	O	O
and	O	O
psychological	O	O
resources	O	O
to	O	O
improve	O	O
the	O	O
health	O	O
of	O	O
women	O	O
with	O	O
HIV	O	B-disease
.	O	O
We	O	O
conclude	O	O
that	O	O
previously	O	O
reported	O	O
hypoglycemia	O	B-disease
,	O	O
hyperbilirubinemia	O	B-disease
,	O	O
polycythemia	O	B-disease
,	O	O
neonatal	O	O
apnea	O	O
,	O	O
and	O	O
bradycardia	O	O
are	O	O
not	O	O
invariable	O	O
and	O	O
cannot	O	O
be	O	O
statistically	O	O
correlated	O	O
with	O	O
chronic	O	O
propranolol	B-disease	B-disease
therapy	O	O
.	O	O
The	O	O
increased	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
products	O	O
containing	O	O
20	O	B-disease
micrograms	O	I-disease
ethinyloestradiol	B-disease	I-disease
and	O	O
desogestrel	B-disease	B-disease
compared	O	O
with	O	O
the	O	O
30	O	B-disease
micrograms	O	I-disease
product	O	I-disease
is	O	O
biologically	O	O
implausible	O	O
,	O	O
and	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
preferential	O	O
prescribing	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
confounding	O	O
.	O	O
The	O	O
DHEA	B-disease	B-disease
was	O	O
administered	O	O
intraperitoneally	O	O
(	O	O
ip	O	O
)	O	O
for	O	O
5	O	O
days	O	O
.	O	O
With	O	O
a	O	O
D	B-disease	B-disease
-	I-disease	I-disease
glucarate	I-disease	I-disease
of	O	O
a	O	O
fixed	O	O
size	O	O
of	O	O
dose	O	O
,	O	O
approximately	O	O
the	O	O
same	O	O
degree	O	O
of	O	O
protection	O	O
was	O	O
obtained	O	O
against	O	O
renal	O	O
damages	O	O
induced	O	O
by	O	O
different	O	O
basic	O	O
antibiotics	O	O
despite	O	O
large	O	O
disparities	O	O
in	O	O
administration	O	O
doses	O	O
of	O	O
different	O	O
antibiotics	O	O
.	O	O
PURPOSE	O	O
:	O	O
Despite	O	O
its	O	O
well	O	O
-	O	O
known	O	O
cardiotoxicity	O	O
,	O	O
the	O	O
anthracyclin	O	B-disease
doxorubicin	B-disease	B-disease
(	O	O
DOX	B-disease	B-disease
)	O	O
continues	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
and	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
.	O	O
Among	O	O
relatively	O	O
healthy	O	O
women	O	O
over	O	O
65	O	O
years	O	O
taking	O	O
continuous	O	O
combined	O	O
HT	O	B-disease
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
dementia	O	O
.	O	O
Three	O	O
minutes	O	O
later	O	O
,	O	O
groups	O	O
were	O	O
challenged	O	O
with	O	O
vehicle	O	O
or	O	O
flumazenil	B-disease	B-disease
5	O	B-disease
or	O	O
10	O	B-disease
mg	O	I-disease
/	O	O
kg	O	B-disease
IP	O	O
.	O	O
CONCLUSIONS	O	O
AND	O	O
CLINICAL	O	O
RELEVANCE	O	O
:	O	O
Results	O	O
suggested	O	O
that	O	O
levetiracetam	B-disease	B-disease
is	O	O
well	O	O
tolerated	O	O
in	O	O
cats	O	O
and	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-disease	B-disease
treatment	O	O
in	O	O
cats	O	O
with	O	O
idiopathic	O	O
epilepsy	O	O
.	O	O
Renal	O	O
failure	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
rifampin	B-disease	B-disease
.	O	O
BACKGROUND	O	O
:	O	O
Acetaminophen	B-disease	B-disease
(	O	O
paracetamol	B-disease	B-disease
-	O	O
-	O	O
P	B-disease	O
)	O	O
and	O	O
Nimesulide	B-disease	B-disease
(	O	O
N	B-disease	O
)	O	O
are	O	O
widely	O	O
used	O	O
analgesic	O	O
-	O	O
antipyretic	O	O
/	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
.	O	O
About	O	O
62	O	O
%	O	O
of	O	O
the	O	O
out	O	O
-	O	O
patients	O	O
developed	O	O
scoline	B-disease	B-disease
pain	O	O
as	O	O
compared	O	O
with	O	O
about	O	O
26	O	O
%	O	O
among	O	O
the	O	O
in	O	O
-	O	O
patients	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
eucalcemic	O	O
patients	O	O
exhibited	O	O
no	O	O
change	O	O
in	O	O
mean	O	O
calcium	B-disease	B-disease
values	O	O
over	O	O
the	O	O
same	O	O
time	O	O
period	O	O
(	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
05	O	O
to	O	O
2	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
05	O	O
mmol	O	B-disease
/	O	I-disease
L	O	I-disease
[	O	O
9	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
2	O	O
to	O	O
9	O	O
.	O	O
2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
2	O	O
mg	O	B-disease
/	O	I-disease
dL	O	I-disease
]	O	O
)	O	O
.	O	O
We	O	O
conclude	O	O
that	O	O
patients	O	O
may	O	O
be	O	O
restarted	O	O
on	O	O
inhaled	O	O
beclomethasone	B-disease	B-disease
when	O	O
clinically	O	O
indicated	O	O
;	O	O
however	O	O
,	O	O
because	O	O
of	O	O
the	O	O
high	O	O
recurrence	O	O
rate	O	O
,	O	O
patients	O	O
who	O	O
develop	O	O
hoarseness	O	O
should	O	O
not	O	O
be	O	O
re	O	O
-	O	O
challenged	O	O
.	O	O
Control	O	O
patients	O	O
received	O	O
infusions	O	O
of	O	O
0	O	O
.	O	O
9	O	O
%	O	O
NaCl	B-disease	B-disease
solution	O	O
.	O	O
His	O	O
laboratory	O	O
values	O	O
showed	O	O
elevated	O	O
creatine	B-disease	B-disease
kinase	O	I-disease
and	O	O
transaminases	O	B-disease
.	O	O
A	O	O
patient	O	O
who	O	O
developed	O	O
paraplegia	O	O
following	O	O
the	O	O
intrathecal	O	O
instillation	O	O
of	O	O
methotrexate	B-disease	B-disease
is	O	O
discribed	O	O
.	O	O
Chlorhexidine	B-disease	B-disease
phosphanilate	I-disease	I-disease
(	O	O
CHP	B-disease	B-disease
)	O	O
,	O	O
a	O	O
new	O	O
broad	O	O
-	O	O
spectrum	O	O
antimicrobial	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
evaluated	O	O
as	O	O
a	O	O
topical	O	O
burn	O	O
wound	O	O
dressing	O	O
in	O	O
cream	O	O
form	O	O
,	O	O
but	O	O
preliminary	O	O
clinical	O	O
trials	O	O
reported	O	O
that	O	O
it	O	O
was	O	O
painful	O	O
upon	O	O
application	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
Initiating	O	O
treatment	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
with	O	O
glibenclamide	B-disease	B-disease
or	O	O
glipizide	B-disease	B-disease
is	O	O
associated	O	O
with	O	O
increased	O	O
risk	O	O
of	O	O
CAD	O	O
in	O	O
comparison	O	O
to	O	O
gliclazide	B-disease	B-disease
or	O	O
glimepiride	B-disease	B-disease
.	O	O
The	O	O
interaction	O	O
is	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
CYP3A4	O	B-disease
-	O	O
mediated	O	O
simvastatin	B-disease	B-disease
clearance	O	O
.	O	O
An	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
was	O	O
given	O	O
halothane	B-disease	B-disease
,	O	O
nitrous	B-disease	B-disease
oxide	I-disease	I-disease
and	O	O
oxygen	B-disease	B-disease
,	O	O
pancuronium	B-disease	B-disease
0	O	I-disease
.	O	I-disease
4	O	I-disease
mg	O	I-disease
and	O	O
suxamethonium	B-disease	B-disease
100	O	I-disease
mg	O	I-disease
for	O	O
induction	O	O
of	O	O
anaesthesia	O	O
.	O	O
Premedication	O	O
of	O	O
diazepam	B-disease	B-disease
10	O	I-disease
mg	O	I-disease
and	O	O
atropine	B-disease	B-disease
0	O	O
.	O	O
5	O	O
mg	O	I-disease
was	O	O
given	O	O
,	O	O
and	O	O
sleep	O	O
was	O	O
induced	O	O
and	O	O
maintained	O	O
by	O	O
intermittent	O	O
intravenous	O	O
injections	O	O
of	O	O
etomidate	B-disease	B-disease
0	O	O
.	O	O
1	O	O
/	O	O
mg	O	I-disease
/	O	O
kg	O	O
,	O	O
given	O	O
whenever	O	O
the	O	O
patient	O	O
would	O	O
open	O	O
his	O	O
eyes	O	O
on	O	O
request	O	O
.	O	O
Patients	O	O
were	O	O
treated	O	O
with	O	O
1	O	O
tablet	O	O
(	O	O
500	O	B-disease
mg	O	I-disease
of	O	I-disease
niacin	B-disease	I-disease
extended	O	I-disease
-	O	I-disease
release	O	I-disease
/	O	O
20	O	B-disease
mg	O	I-disease
of	O	I-disease
lovastatin	B-disease	I-disease
)	O	O
once	O	O
nightly	O	O
for	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
2	O	O
tablets	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O
This	O	O
case	O	O
demonstrates	O	O
the	O	O
selective	O	O
vulnerability	O	O
of	O	O
the	O	O
anterior	O	O
visual	O	O
pathways	O	O
and	O	O
peripheral	O	O
nerves	O	O
to	O	O
ethambutol	B-disease	B-disease
toxicity	O	O
.	O	O
Adriamycin	B-disease	B-disease
in	O	O
the	O	O
cumulative	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
evoked	O	O
fully	O	O
developed	O	O
cardiac	O	O
toxicity	O	O
.	O	O
Possible	O	O
pathophysiological	O	O
mechanisms	O	O
which	O	O
may	O	O
have	O	O
been	O	O
operative	O	O
in	O	O
this	O	O
case	O	O
include	O	O
:	O	O
a	O	O
direct	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
toxic	O	O
effect	O	O
of	O	O
valproic	B-disease	B-disease
acid	I-disease	I-disease
;	O	O
a	O	O
paradoxical	O	O
epileptogenic	O	O
effect	O	O
secondary	O	O
to	O	O
the	O	O
drug	O	O
;	O	O
and	O	O
an	O	O
indirect	O	O
CNS	O	O
toxic	O	O
effect	O	O
mediated	O	O
through	O	O
valproic	B-disease	B-disease
acid	I-disease	I-disease
-	O	O
induced	O	O
hyperammonemia	O	B-disease
.	O	O
The	O	O
antidepressant	O	O
trazodone	B-disease	B-disease
is	O	O
a	O	O
5	B-disease	O
-	I-disease	O
HT	I-disease	O
2A	O	O
/	O	O
2C	O	O
receptor	O	O
antagonist	O	O
.	O	O
All	O	O
patients	O	O
recovered	O	O
their	O	O
previous	O	O
normal	O	O
renal	O	O
function	O	O
after	O	O
adequate	O	O
hydration	O	B-disease
and	O	O
alcalinization	O	B-disease
.	O	O
Changes	O	O
in	O	O
intragastric	O	O
pressure	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
suxamethonium	B-disease	B-disease
1	O	I-disease
.	O	I-disease
5	O	I-disease
mg	O	I-disease
kg	O	I-disease
-	O	I-disease
1	O	I-disease
i	O	I-disease
.	O	I-disease
v	O	I-disease
.	O	I-disease
were	O	O
studied	O	O
in	O	O
32	O	O
children	O	O
(	O	O
mean	O	O
age	O	O
6	O	O
.	O	O
9	O	O
yr	O	O
)	O	O
pretreated	O	O
with	O	O
either	O	O
physiological	O	B-disease
saline	O	I-disease
or	O	O
alfentanil	B-disease	B-disease
50	O	I-disease
micrograms	O	I-disease
kg	O	I-disease
-	O	I-disease
1	O	I-disease
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
neurotoxicity	O	O
of	O	O
theophylline	B-disease	B-disease
is	O	O
altered	O	O
in	O	O
advanced	O	O
pregnancy	O	O
.	O	O
Patients	O	O
were	O	O
interviewed	O	O
personally	O	O
later	O	O
the	O	O
same	O	O
day	O	O
,	O	O
and	O	O
by	O	O
questionnaire	O	O
three	O	O
to	O	O
four	O	O
weeks	O	O
later	O	O
.	O	O
By	O	O
routinely	O	O
monitoring	O	O
serum	O	B-disease
calcium	B-disease	I-disease
levels	O	O
,	O	O
healthcare	O	O
providers	O	O
can	O	O
improve	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
this	O	O
patient	O	O
group	O	O
.	O	O
OIH	O	O
was	O	O
achieved	O	O
in	O	O
mice	O	O
after	O	O
subcutaneous	O	O
administration	O	O
of	O	O
morphine	B-disease	B-disease
for	O	O
7	O	O
consecutive	O	O
days	O	O
three	O	O
times	O	O
per	O	O
day	O	O
.	O	O
This	O	O
case	O	O
represents	O	O
the	O	O
most	O	O
thoroughly	O	O
investigated	O	O
case	O	O
of	O	O
amiodarone	B-disease	B-disease
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
with	O	O
a	O	O
history	O	O
significant	O	O
for	O	O
subclinical	O	O
thyroid	O	O
disease	O	O
.	O	O
Erdosteine	B-disease	B-disease
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
the	O	O
extent	O	O
of	O	O
tubular	O	O
damage	O	O
.	O	O
These	O	O
cases	O	O
call	O	O
attention	O	O
to	O	O
possible	O	O
paranoid	O	O
exacerbations	O	O
with	O	O
serotonin	B-disease	B-disease
reuptake	O	I-disease
blockers	O	I-disease
in	O	O
select	O	O
patients	O	O
and	O	O
raise	O	O
neurobiological	O	O
considerations	O	O
regarding	O	O
paranoia	O	O
.	O	O
Two	O	O
hundred	O	O
four	O	O
people	O	O
with	O	O
epilepsy	O	O
were	O	O
grouped	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
antiepileptic	O	O
drug	O	O
therapy	O	O
(	O	O
current	O	O
,	O	O
previous	O	O
,	O	O
or	O	O
no	O	O
exposure	O	O
to	O	O
VGB	B-disease	B-disease
)	O	O
.	O	O
The	O	O
relevance	O	O
of	O	O
these	O	O
features	O	O
for	O	O
patients	O	O
using	O	O
PDN	B-disease	B-disease
remains	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O
hCRH	O	B-disease
and	O	O
TRH	O	B-disease
caused	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
CO2	B-disease	B-disease
threshold	O	O
.	O	O
Eslicarbazepine	B-disease	B-disease
acetate	I-disease	I-disease
(	O	O
BIA	B-disease	B-disease
2	I-disease	I-disease
-	I-disease	I-disease
093	I-disease	I-disease
,	O	O
S	B-disease	B-disease
-	I-disease	I-disease
(	I-disease	I-disease
-	I-disease	I-disease
)	I-disease	I-disease
-	I-disease	I-disease
10	I-disease	I-disease
-	I-disease	I-disease
acetoxy	I-disease	I-disease
-	I-disease	I-disease
10	I-disease	I-disease
,	I-disease	I-disease
11	I-disease	I-disease
-	I-disease	I-disease
dihydro	I-disease	I-disease
-	I-disease	I-disease
5H	I-disease	I-disease
-	I-disease	I-disease
dibenzo	I-disease	I-disease
/	I-disease	I-disease
b	I-disease	I-disease
,	I-disease	I-disease
f	I-disease	I-disease
/	I-disease	I-disease
azepine	I-disease	I-disease
-	I-disease	I-disease
5	I-disease	I-disease
-	I-disease	I-disease
carboxamide	I-disease	I-disease
)	O	O
is	O	O
a	O	O
novel	O	O
antiepileptic	O	O
drug	O	O
,	O	O
now	O	O
in	O	O
Phase	O	O
III	O	O
clinical	O	O
trials	O	O
,	O	O
designed	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
structurally	O	O
related	O	O
drugs	O	O
carbamazepine	B-disease	B-disease
(	O	I-disease
CBZ	B-disease	I-disease
)	O	I-disease
and	O	O
oxcarbazepine	B-disease	B-disease
(	O	I-disease
OXC	B-disease	I-disease
)	O	I-disease
.	O	O
Reducing	O	O
harm	O	O
associated	O	O
with	O	O
anticoagulation	O	B-disease
:	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B-disease	B-disease
therapy	O	O
in	O	O
heparin	B-disease	B-disease
-	O	O
induced	O	O
thrombocytopenia	O	B-disease
.	O	O
Erdosteine	B-disease	B-disease
showed	O	O
histopathological	O	O
protection	O	O
against	O	O
VCM	B-disease	O
-	O	O
induced	O	O
nephrotoxicity	O	O
.	O	O
Carbimazole	B-disease	B-disease
induced	O	O
ANCA	O	O
positive	O	O
vasculitis	O	O
.	O	O
Left	O	O
ventricular	O	O
function	O	O
(	O	O
assessed	O	O
by	O	O
echocardiography	O	O
)	O	O
showed	O	O
that	O	O
PPA	B-disease	B-disease
increased	O	O
the	O	O
stroke	O	O
volume	O	O
30	O	O
%	O	O
(	O	O
from	O	O
62	O	O
.	O	O
5	O	O
+	O	O
/	O	O
-	O	O
20	O	O
.	O	O
9	O	O
to	O	O
80	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O
22	O	O
.	O	O
4	O	O
ml	O	O
)	O	O
,	O	O
the	O	O
ejection	O	O
fraction	O	O
9	O	O
%	O	O
(	O	O
from	O	O
64	O	O
%	O	O
+	O	O
/	O	O
-	O	O
10	O	O
%	O	O
to	O	O
70	O	O
%	O	O
+	O	O
/	O	O
-	O	O
7	O	O
%	O	O
)	O	O
,	O	O
and	O	O
cardiac	O	O
output	O	O
14	O	O
%	O	O
(	O	O
from	O	O
3	O	O
.	O	O
6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
6	O	O
to	O	O
4	O	O
.	O	O
1	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O
0	O	O
L	O	O
/	O	O
min	O	O
)	O	O
.	O	O
Evaluation	O	O
revealed	O	O
the	O	O
syndrome	O	O
of	O	O
inappropriate	O	O
secretion	O	O
of	O	O
antidiuretic	O	B-disease
hormone	O	I-disease
,	O	O
which	O	O
was	O	O
attributed	O	O
to	O	O
the	O	O
vincristine	B-disease	B-disease
infusion	O	O
.	O	O
Coronary	O	O
blood	O	O
flow	O	O
,	O	O
cardiac	O	O
work	O	O
and	O	O
metabolism	O	O
were	O	O
studied	O	O
in	O	O
dogs	O	O
under	O	O
sodium	B-disease	B-disease
nitroprusside	I-disease	I-disease
(	O	O
SNP	B-disease	B-disease
)	O	O
and	O	O
trimetaphan	B-disease	B-disease
(	O	O
TMP	B-disease	B-disease
)	O	O
deliberate	O	O
hypotension	O	O
(	O	O
20	O	O
%	O	O
and	O	O
40	O	O
%	O	O
mean	O	O
pressure	O	O
decrease	O	O
from	O	O
baseline	O	O
)	O	O
.	O	O
In	O	O
the	O	O
presence	O	O
of	O	O
coronary	O	O
artery	O	O
stenosis	O	O
,	O	O
3	O	O
-	O	O
min	O	O
periods	O	O
of	O	O
intracoronary	O	O
ISO	B-disease	B-disease
infusion	O	O
(	O	O
10	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
maximal	O	O
rate	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
rise	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
of	O	O
the	O	O
epicardial	O	O
electrocardiogram	O	O
.	O	O
After	O	O
thalidomide	B-disease	B-disease
treatment	O	O
,	O	O
sural	O	O
SAP	O	O
amplitude	O	O
recovered	O	O
in	O	O
3	O	O
patients	O	O
.	O	O
The	O	O
data	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
S	O	O
.	O	O
virgaurea	O	I-disease
extract	O	O
exerts	O	O
its	O	O
protective	O	O
effect	O	O
by	O	O
decreasing	O	O
MDA	B-disease	B-disease
level	O	O
and	O	O
increasing	O	O
the	O	O
antioxidant	O	O
status	O	O
in	O	O
isoproterenol	B-disease	B-disease
-	O	O
treated	O	O
rats	O	O
.	O	O
Since	O	O
mesangial	O	O
CC	O	B-disease
clearance	O	O
from	O	O
the	O	O
mesangium	O	O
did	O	O
not	O	O
change	O	O
during	O	O
chronic	O	O
PAN	B-disease	B-disease
treatment	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
this	O	O
preferential	O	O
CC	O	B-disease
localization	O	O
within	O	O
the	O	O
lesions	O	O
is	O	O
caused	O	O
by	O	O
an	O	O
increased	O	O
CC	O	B-disease
uptake	O	O
shortly	O	O
after	O	O
injection	O	O
in	O	O
apparent	O	O
vulnerable	O	O
areas	O	O
where	O	O
sclerosis	O	O
will	O	O
develop	O	O
subsequently	O	O
.	O	O
It	O	O
is	O	O
considered	O	O
unlikely	O	O
that	O	O
etomidate	B-disease	B-disease
will	O	O
prove	O	O
to	O	O
be	O	O
the	O	O
hypnotic	O	O
of	O	O
choice	O	O
for	O	O
a	O	O
totally	O	O
intravenous	O	O
anesthetic	O	O
technique	O	O
in	O	O
adults	O	O
because	O	O
of	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
myoclonia	O	O
after	O	O
prolonged	O	O
administration	O	O
.	O	O
Efficacy	O	O
of	O	O
olanzapine	B-disease	B-disease
in	O	O
acute	O	O
bipolar	O	O
mania	O	O
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
.	O	O
RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
49	O	O
patients	O	O
(	O	O
median	O	O
age	O	O
:	O	O
60	O	O
;	O	O
range	O	O
41	O	O
-	O	O
81	O	O
)	O	O
entered	O	O
this	O	O
phase	O	O
2	O	O
trial	O	O
.	O	O
The	O	O
initial	O	O
response	O	O
to	O	O
the	O	O
primary	O	O
attack	O	O
by	O	O
the	O	O
cyclophosphamide	B-disease	B-disease
metabolites	O	O
seems	O	O
to	O	O
be	O	O
fragmentation	O	O
of	O	O
the	O	O
luminal	B-disease	O
membrane	O	O
.	O	O
Busulfan	B-disease	B-disease
is	O	O
known	O	O
to	O	O
be	O	O
neurotoxic	O	O
in	O	O
animals	O	O
and	O	O
humans	O	O
,	O	O
but	O	O
its	O	O
acute	O	O
neurotoxicity	O	O
remains	O	O
poorly	O	O
characterized	O	O
in	O	O
children	O	O
.	O	O
Frequent	O	O
and	O	O
early	O	O
monitoring	O	O
for	O	O
these	O	O
toxicities	O	O
is	O	O
warranted	O	O
in	O	O
developing	O	O
countries	O	O
where	O	O
generic	O	O
HAART	O	B-disease
is	O	O
increasingly	O	O
available	O	O
.	O	O
Heparin	B-disease	B-disease
-	O	O
induced	O	O
thrombocytopenia	O	O
,	O	O
paradoxical	O	O
thromboembolism	O	O
,	O	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B-disease	B-disease
therapy	O	O
.	O	O
Theophylline	B-disease	B-disease
serum	O	O
protein	O	O
binding	O	O
determined	O	O
by	O	O
equilibrium	O	O
dialysis	O	O
was	O	O
lower	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O
Intravenous	O	O
or	O	O
intratracheal	O	O
inoculation	O	O
of	O	O
2	O	O
.	O	O
0	O	O
to	O	I-disease
2	O	O
.	O	O
5	O	O
mg	O	I-disease
of	O	O
vincristine	B-disease	B-disease
sulfate	I-disease	I-disease
was	O	O
followed	O	O
by	O	O
leukopenia	O	O
in	O	O
4	O	O
to	O	O
5	O	O
days	O	O
.	O	O
Caffeine	B-disease	B-disease
challenge	O	O
test	O	O
in	O	O
panic	O	O
disorder	O	O
and	O	O
depression	O	O
with	O	O
panic	O	O
attacks	O	O
.	O	O
MK	B-disease	O
-	I-disease	O
801	I-disease	O
augments	O	O
pilocarpine	B-disease	B-disease
-	O	O
induced	O	O
electrographic	O	O
seizure	O	O
but	O	O
protects	O	O
against	O	O
brain	O	O
damage	O	O
in	O	O
rats	O	O
.	O	O
RESULTS	O	O
:	O	O
Controlled	O	O
hypotension	O	O
was	O	O
achieved	O	O
within	O	O
a	O	O
shorter	O	O
period	O	O
using	O	O
laryngeal	O	O
mask	O	O
using	O	O
lower	O	O
rates	O	O
of	O	O
remifentanil	B-disease	B-disease
infusion	O	O
and	O	O
lower	O	O
total	O	O
dose	O	O
of	O	O
remifentanil	B-disease	B-disease
.	O	O
Deterioration	O	O
of	O	O
vision	O	O
occurred	O	O
despite	O	O
withdrawal	O	O
of	O	O
ethambutol	B-disease	B-disease
.	O	O
After	O	O
sacrifice	O	O
the	O	O
hearts	O	O
of	O	O
doxorubicin	B-disease	B-disease
-	O	O
treated	O	O
animals	O	O
were	O	O
enlarged	O	O
and	O	O
the	O	O
atria	O	O
were	O	O
hypertrophic	O	O
.	O	O
Epinephrine	B-disease	B-disease
dysrhythmogenicity	O	O
is	O	O
not	O	O
enhanced	O	O
by	O	O
subtoxic	O	O
bupivacaine	B-disease	B-disease
in	O	O
dogs	O	O
.	O	O
We	O	O
report	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
hypertension	O	O
(	O	O
blood	O	O
pressure	O	O
190	O	O
/	O	O
160	O	O
)	O	O
in	O	O
a	O	O
4	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
neuroblastoma	O	O
who	O	O
was	O	O
given	O	O
Imipramine	B-disease	B-disease
to	O	O
control	O	O
a	O	O
behavior	O	O
disorder	O	O
.	O	O
The	O	O
case	O	O
shows	O	O
that	O	O
prolonged	O	O
jaw	O	O
rigidity	O	O
and	O	O
myalgia	O	O
may	O	O
occur	O	O
after	O	O
suxamethonium	B-disease	B-disease
in	O	O
patients	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
despite	O	O
pretreatment	O	O
with	O	O
pancuronium	B-disease	B-disease
.	O	O
RESULTS	O	O
:	O	O
CIN	O	B-disease
was	O	O
detected	O	O
in	O	O
18	O	O
/	O	O
90	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
.	O	O
The	O	O
serum	O	O
FBAL	B-disease	B-disease
concentration	O	O
subsequently	O	O
decreased	O	O
to	O	O
352	O	B-disease
ng	O	I-disease
/	O	I-disease
ml	O	I-disease
,	O	O
the	O	O
same	O	O
as	O	O
the	O	O
value	O	O
measured	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
S	O	B-disease
-	O	I-disease
1	O	I-disease
administration	O	O
.	O	O
The	O	O
diagnosis	O	O
of	O	O
P	B-disease	B-disease
and	O	O
N	B-disease	B-disease
-	O	O
induced	O	O
skin	O	O
reactions	O	O
was	O	O
based	O	O
in	O	O
vivo	O	O
challenge	O	O
.	O	O
We	O	O
report	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
end	O	O
-	O	O
stage	O	O
renal	O	O
disease	O	O
receiving	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
,	O	O
who	O	O
developed	O	O
slurred	O	O
speech	O	O
,	O	O
tremor	O	O
,	O	O
bizarre	O	O
behavior	O	O
,	O	O
progressive	O	O
mental	O	O
confusion	O	O
,	O	O
and	O	O
2	O	O
episodes	O	O
of	O	O
generalized	O	O
tonic	O	O
-	O	O
clonic	O	O
seizure	O	O
(	O	O
GTCS	O	O
)	O	O
after	O	O
5	O	O
doses	O	O
of	O	O
piperacillin	B-disease	B-disease
/	I-disease	O
tazobactam	I-disease	B-disease
(	O	O
2	O	O
g	O	O
/	O	O
250	O	O
mg	O	O
)	O	O
were	O	O
given	O	O
for	O	O
bronchiectasis	O	O
with	O	O
secondary	O	O
infection	O	O
.	O	O
Two	O	O
patients	O	O
developed	O	O
device	O	O
-	O	O
related	O	O
complications	O	O
and	O	O
two	O	O
patients	O	O
experienced	O	O
abnormal	O	O
weight	O	B-disease
gain	O	I-disease
.	O	O
Nelarabine	B-disease	B-disease
neurotoxicity	O	O
with	O	O
concurrent	O	O
intrathecal	O	O
chemotherapy	O	B-disease
:	O	O
Case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O
A	O	O
6	O	O
-	O	O
week	O	O
open	O	O
study	O	O
of	O	O
the	O	O
introduction	O	O
of	O	O
isradipine	B-disease	B-disease
treatment	O	O
was	O	O
conducted	O	O
in	O	O
general	O	O
practice	O	O
in	O	O
Hong	O	O
Kong	O	O
.	O	O
In	O	O
vitro	O	O
perfusion	O	O
of	O	O
bepridil	B-disease	B-disease
in	O	O
the	O	O
life	O	O
-	O	O
support	O	O
medium	O	O
for	O	O
isolated	O	O
sino	O	O
-	O	O
atrial	O	O
tissue	O	O
from	O	O
rabbit	O	O
heart	O	O
,	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
action	O	O
potential	O	O
(	O	O
AP	O	O
)	O	O
spike	O	O
frequency	O	O
(	O	O
recorded	O	O
by	O	O
KCl	B-disease	B-disease
microelectrodes	O	O
)	O	O
starting	O	O
at	O	O
doses	O	O
of	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	B-disease
.	O	O
CONCLUSIONS	O	O
:	O	O
Children	O	O
treated	O	O
with	O	O
indinavir	B-disease	B-disease
have	O	O
a	O	O
high	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	O	O
.	O	O
Definite	O	O
,	O	O
although	O	O
limited	O	O
,	O	O
antineoplastic	O	O
activity	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
well	O	O
-	O	O
defined	O	O
platinum	B-disease	B-disease
-	O	O
and	O	O
paclitaxel	B-disease	B-disease
-	O	O
refractory	O	O
ovarian	O	O
cancer	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
precipitating	O	O
cause	O	O
of	O	O
convulsions	O	O
was	O	O
believed	O	O
to	O	O
be	O	O
an	O	O
overdose	O	O
of	O	O
TNA	B-disease	B-disease
.	O	O
A	O	O
very	O	O
rare	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
amlodipine	B-disease	B-disease
is	O	O
dysguesia	O	O
.	O	O
DESIGN	O	O
:	O	O
Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
received	O	O
100	O	B-disease
mg	O	I-disease
/	O	I-disease
kg	O	I-disease
cocaine	B-disease	I-disease
IP	O	O
alone	O	O
,	O	O
5	O	B-disease
mg	O	I-disease
/	O	I-disease
kg	O	I-disease
diazepam	B-disease	I-disease
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
diazepam	B-disease	B-disease
and	O	O
cocaine	B-disease	B-disease
.	O	O
In	O	O
5	O	O
consecutive	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
who	O	O
received	O	O
intravenous	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-disease	B-disease
(	O	O
MP	B-disease	O
)	O	O
therapy	O	O
(	O	O
1	O	O
g	O	O
daily	O	O
for	O	O
2	O	O
or	O	O
3	O	O
consecutive	O	O
days	O	O
)	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
pulse	O	O
rate	O	O
was	O	O
observed	O	O
,	O	O
most	O	O
pronounced	O	O
on	O	O
day	O	O
4	O	O
.	O	O
After	O	O
adrenaline	B-disease	B-disease
infusion	O	O
for	O	O
30	O	O
s	O	O
,	O	O
there	O	O
were	O	O
large	O	O
unstained	O	O
areas	O	O
in	O	O
the	O	O
left	O	O
brain	O	O
in	O	O
right	O	O
-	O	O
pawed	O	O
animals	O	O
,	O	O
and	O	O
vice	O	O
versa	O	O
in	O	O
left	O	O
-	O	O
pawed	O	O
animals	O	O
.	O	O
Gentamicin	B-disease	B-disease
-	O	O
induced	O	O
nephropathy	O	O
may	O	O
at	O	O
least	O	O
in	O	O
part	O	O
be	O	O
causally	O	O
related	O	O
with	O	O
a	O	O
decreased	O	O
expression	O	O
of	O	O
Na	B-disease	B-disease
(	O	I-disease
+	O	I-disease
)	O	I-disease
/	O	I-disease
K	B-disease	I-disease
(	O	I-disease
+	O	I-disease
)	O	I-disease
-	O	I-disease
ATPase	O	I-disease
,	O	O
NHE3	O	B-disease
,	O	O
NBC1	O	B-disease
,	O	O
AQP1	O	B-disease
and	O	O
OAT	O	B-disease
.	O	O
Tubular	O	O
proteinuria	O	O
and	O	O
oxidative	O	O
stress	O	O
were	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
maleate	B-disease	B-disease
(	O	O
400	O	B-disease
mg	O	I-disease
/	O	I-disease
kg	O	I-disease
)	O	O
in	O	O
rats	O	O
.	O	O
Physicians	O	O
should	O	O
recognise	O	O
the	O	O
possibility	O	O
of	O	O
fatal	O	O
bacterial	O	O
infections	O	O
related	O	O
to	O	O
bortezomib	B-disease	B-disease
plus	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-disease	B-disease
in	O	O
elderly	O	O
patients	O	O
,	O	O
and	O	O
we	O	O
believe	O	O
this	O	O
case	O	O
warrants	O	O
further	O	O
investigation	O	O
.	O	O
We	O	O
report	O	O
on	O	O
rosaceiform	O	O
dermatitis	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B-disease	B-disease
ointment	O	I-disease
.	O	O
Patients	O	O
with	O	O
New	O	O
York	O	O
Heart	O	O
Association	O	O
classes	O	O
II	O	O
to	O	O
IV	O	O
CHF	O	O
and	O	O
left	O	O
ventricular	O	O
ejection	O	O
fractions	O	O
of	O	O
no	O	O
greater	O	O
than	O	O
0	O	O
.	O	O
30	O	O
(	O	O
n	O	O
=	O	O
3164	O	B-disease
)	O	O
were	O	O
randomized	O	O
and	O	O
followed	O	O
up	O	O
for	O	O
a	O	O
median	O	O
of	O	O
46	O	O
months	O	O
.	O	O
We	O	O
found	O	O
19	O	O
trials	O	O
,	O	O
involving	O	O
2441	O	O
patients	O	O
treated	O	O
by	O	O
VNR	B-disease	B-disease
and	O	O
2050	O	O
control	O	O
patients	O	O
.	O	O
The	O	O
influence	O	O
of	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B-disease	B-disease
and	O	O
doxorubicin	B-disease	B-disease
administration	O	O
on	O	O
the	O	O
protection	O	O
against	O	O
doxorubicin	B-disease	B-disease
-	O	O
induced	O	O
cardiotoxicity	O	O
in	O	O
mice	O	O
.	O	O
Coronary	O	O
vasospasm	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
non	O	O
-	O	O
selective	O	O
beta	O	O
-	O	O
blocking	O	O
properties	O	O
of	O	O
sotalol	B-disease	B-disease
.	O	O
RATIONALE	O	O
:	O	O
5	B-disease	B-disease
-	I-disease	I-disease
Hydroxytryptamine	I-disease	I-disease
,	O	O
via	O	O
stimulation	O	O
of	O	O
5	B-disease	B-disease
-	I-disease	I-disease
HT	I-disease	I-disease
2C	O	I-disease
receptors	O	I-disease
,	O	O
exerts	O	O
a	O	O
tonic	O	O
inhibitory	O	O
influence	O	O
on	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
whereas	O	O
activation	O	O
of	O	O
5	B-disease	B-disease
-	I-disease	I-disease
HT	I-disease	I-disease
2A	O	I-disease
receptors	O	I-disease
enhances	O	O
stimulated	O	O
DAergic	O	O
neurotransmission	O	O
.	O	O
ILK	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
also	O	O
showed	O	O
increased	O	O
expression	O	O
of	O	O
key	O	O
genes	O	O
involved	O	O
in	O	O
hepatocyte	O	O
proliferation	O	O
at	O	O
different	O	O
time	O	O
points	O	O
during	O	O
PB	B-disease	B-disease
administration	O	O
.	O	O
To	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
heart	O	O
disease	O	O
in	O	O
outpatient	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-disease	B-disease
users	O	O
,	O	O
35	O	O
cocaine	B-disease	B-disease
users	O	O
and	O	O
32	O	O
age	O	O
-	O	O
matched	O	O
controls	O	O
underwent	O	O
resting	O	O
and	O	O
exercise	O	O
electrocardiography	O	O
(	O	O
ECG	O	O
)	O	O
and	O	O
Doppler	O	O
echocardiography	O	O
.	O	O
These	O	O
values	O	O
were	O	O
greater	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
.	O	O
Flurothyl	B-disease	B-disease
ether	B-disease	I-disease
produced	O	O
hypothermia	O	O
which	O	O
was	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
flurothyl	B-disease	B-disease
exposure	O	O
;	O	O
however	O	O
,	O	O
the	O	O
relationship	O	O
of	O	O
hypothermia	O	O
to	O	O
seizure	O	O
induction	O	O
was	O	O
unclear	O	O
.	O	O
METHODS	O	O
:	O	O
The	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
trazodone	B-disease	B-disease
on	O	O
dexamphetamine	B-disease	B-disease
-	O	O
and	O	O
apomorphine	B-disease	B-disease
-	O	O
induced	O	O
oral	O	O
stereotypies	O	O
,	O	O
on	O	O
catalepsy	O	O
induced	O	O
by	O	O
haloperidol	B-disease	B-disease
and	O	O
apomorphine	B-disease	B-disease
(	O	O
0	O	O
.	O	O
05	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
,	O	O
on	O	O
ergometrine	B-disease	B-disease
-	O	O
induced	O	O
wet	O	O
dog	O	O
shake	O	O
(	O	O
WDS	O	O
)	O	O
behavior	O	O
and	O	O
fluoxetine	B-disease	B-disease
-	O	O
induced	O	O
penile	O	O
erections	O	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O
Gemfibrozil	B-disease	B-disease
-	O	O
lovastatin	B-disease	B-disease
therapy	O	O
for	O	O
primary	O	O
hyperlipoproteinemias	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
status	O	O
epilepticus	O	O
was	O	O
induced	O	O
by	O	O
systemic	O	O
injection	O	O
of	O	O
pilocarpine	B-disease	B-disease
in	O	O
rats	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
and	O	O
dose	O	O
-	O	O
effect	O	O
relationships	O	O
of	O	O
the	O	O
antagonism	O	O
of	O	O
picrotoxin	B-disease	B-disease
-	O	O
induced	O	O
seizures	O	O
by	O	O
cholecystokinin	B-disease	B-disease
,	O	O
fragments	O	O
and	O	O
analogues	O	O
of	O	O
cholecystokinin	B-disease	B-disease
in	O	O
mice	O	O
.	O	O
Cyclical	O	B-disease
low	O	I-disease
-	O	I-disease
dose	O	I-disease
oestrogen	B-disease	I-disease
therapy	O	O
with	O	O
7	O	O
-	O	O
-	O	O
13	O	O
days	O	O
of	O	O
progestagen	B-disease	B-disease
does	O	O
not	O	O
seem	O	O
to	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
endometrial	O	O
hyperplasia	O	O
or	O	O
carcinoma	O	O
.	O	O
Forty	O	O
-	O	O
eight	O	O
hours	O	O
after	O	O
the	O	O
final	O	O
exercise	O	O
period	O	O
,	O	O
S	O	O
-	O	O
I	O	O
and	O	O
E	O	O
-	O	O
I	O	O
animals	O	O
received	O	O
a	O	O
single	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-disease	B-disease
(	O	O
250	O	B-disease
mg	O	I-disease
/	O	I-disease
kg	O	I-disease
body	O	O
weight	O	O
)	O	O
.	O	O
Also	O	O
,	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
SVR	O	O
)	O	O
decreased	O	O
during	O	O
the	O	O
eight	O	O
-	O	O
minute	O	O
observation	O	O
period	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O
Rather	O	O
,	O	O
BNPP	B-disease	B-disease
pretreatment	O	O
reduced	O	O
the	O	O
fraction	O	O
of	O	O
APAP	B-disease	B-disease
excreted	O	O
as	O	O
PAP	B-disease	B-disease
by	O	O
64	O	O
and	O	O
75	O	O
%	O	O
after	O	O
APAP	B-disease	B-disease
doses	O	O
of	O	O
750	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
during	O	O
suxamethonium	B-disease	B-disease
-	O	O
induced	O	O
muscle	O	O
fasciculations	O	O
in	O	O
children	O	O
:	O	O
inhibition	O	O
by	O	O
alfentanil	B-disease	B-disease
.	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
PAP	B-disease	B-disease
formation	O	O
is	O	O
a	O	O
requisite	O	O
step	O	O
in	O	O
APAP	B-disease	B-disease
-	O	O
induced	O	O
nephrotoxicity	O	O
.	O	O
There	O	O
is	O	O
considerable	O	O
interest	O	O
in	O	O
identifying	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
relate	O	O
early	O	O
-	O	O
life	O	O
iAs	B-disease	B-disease
exposure	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
latent	O	O
diseases	O	O
,	O	O
particularly	O	O
in	O	O
relationship	O	O
to	O	O
cancer	O	O
.	O	O
Fluoxetine	B-disease	B-disease
on	O	O
its	O	O
own	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
proliferating	O	O
cell	O	O
number	O	O
or	O	O
behaviour	O	O
.	O	O
Tonic	O	O
dopaminergic	O	B-disease
stimulation	O	O
impairs	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O
In	O	O
the	O	O
non	O	O
-	O	O
pretreatment	O	O
group	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
decreased	O	O
from	O	O
107	O	O
.	O	O
4	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O
4	O	O
mmHg	O	O
to	O	O
86	O	O
.	O	O
7	O	O
+	O	O
/	O	O
-	O	O
11	O	O
.	O	O
4	O	O
mmHg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
two	O	O
minutes	O	O
after	O	O
cimetidine	B-disease	B-disease
.	O	O
Following	O	O
GEM	B-disease	O
-	O	O
P	O	O
,	O	O
5	O	O
-	O	O
year	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
was	O	O
46	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	B-disease
)	O	O
,	O	O
30	O	O
-	O	O
62	O	O
%	O	O
)	O	O
and	O	O
5	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
was	O	O
59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	B-disease
,	O	O
43	O	O
-	O	O
74	O	O
%	O	O
)	O	O
.	O	O
When	O	O
participants	O	O
were	O	O
stratified	O	O
by	O	O
antiretroviral	O	B-disease
therapy	O	I-disease
(	O	O
ART	O	O
)	O	O
use	O	O
,	O	O
the	O	O
association	O	O
between	O	O
alcohol	B-disease	B-disease
and	O	O
CD4	O	B-disease
+	O	I-disease
T	O	I-disease
-	O	I-disease
cell	O	I-disease
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
.	O	O
This	O	O
complication	O	O
may	O	O
result	O	O
from	O	O
an	O	O
inhibition	O	O
of	O	O
prostaglandin	B-disease	B-disease
synthesis	O	O
and	O	O
consequent	O	O
hyporeninemic	O	O
hypoaidosteronism	O	B-disease
.	O	O
Baboon	O	O
syndrome	O	O
is	O	O
a	O	O
drug	O	B-disease
-	O	O
or	O	O
contact	O	O
allergen	O	B-disease
-	O	O
related	O	O
maculopapular	O	O
eruption	O	O
that	O	O
typically	O	O
involves	O	O
the	O	O
flexural	O	O
and	O	O
gluteal	O	O
areas	O	O
.	O	O
Use	O	O
of	O	O
propranolol	B-disease	B-disease
in	O	O
the	O	O
treatment	O	O
of	O	O
idiopathic	O	O
orthostatic	O	O
hypotension	O	O
.	O	O
METHODS	O	O
:	O	O
Urinary	O	B-disease
pH	O	I-disease
,	O	O
albumin	O	B-disease
,	O	O
creatinine	B-disease	B-disease
,	O	O
the	O	O
presence	O	O
of	O	O
erythrocytes	O	B-disease
,	O	O
leukocytes	O	B-disease
,	O	O
bacteria	O	O
and	O	O
crystals	O	O
,	O	O
and	O	O
culture	O	O
were	O	O
analyzed	O	O
every	O	O
3	O	O
months	O	O
for	O	O
96	O	O
weeks	O	O
.	O	O
Acute	O	O
morphine	B-disease	B-disease
(	O	O
30mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O
c	O	O
.	O	O
)	O	O
treatment	O	O
significantly	O	O
attenuated	O	O
hippocampal	O	O
LTP	O	O
and	O	O
CCK	B-disease	B-disease
-	I-disease	I-disease
8	I-disease	I-disease
(	O	O
1ug	O	O
,	O	O
i	O	O
.	O	O
c	O	O
.	O	O
v	O	O
.	O	O
)	O	O
restored	O	O
the	O	O
amplitude	O	O
of	O	O
PS	O	O
that	O	O
was	O	O
attenuated	O	O
by	O	O
morphine	B-disease	B-disease
injection	O	O
.	O	O
To	O	O
confirm	O	O
the	O	O
pro	O	O
-	O	O
apoptotic	O	O
effects	O	O
,	O	O
we	O	O
performed	O	O
flow	O	O
cytometric	O	O
detection	O	O
,	O	O
cardiac	O	O
histology	O	O
,	O	O
transmission	O	O
electron	O	O
microscopy	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	B-disease
transferase	O	I-disease
-	O	O
mediated	O	O
dUTP	B-disease	B-disease
-	O	O
biotin	B-disease	O
nick	O	O
end	O	O
labeling	O	O
assay	O	O
.	O	O
Our	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
ginsenoside	B-disease	B-disease
Re	I-disease	I-disease
,	O	O
but	O	O
not	O	O
Rg1	B-disease	B-disease
or	O	O
Rb1	B-disease	B-disease
,	O	O
may	O	O
contribute	O	O
toward	O	O
reversal	O	O
of	O	O
OIH	O	O
.	O	O
In	O	O
these	O	O
animals	O	O
,	O	O
abecarnil	B-disease	B-disease
produced	O	O
a	O	O
paralleled	O	O
dose	O	O
-	O	O
dependent	O	O
(	O	O
0	O	O
.	O	O
05	O	O
-	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
p	O	O
.	O	O
)	O	O
reduction	O	O
of	O	O
both	O	O
motor	O	O
behavior	O	O
and	O	O
cortical	O	O
[	O	O
35S	O	B-disease
]	O	O
TBPS	O	B-disease
binding	O	O
.	O	O
ACC	B-disease	B-disease
-	I-disease	I-disease
9653	I-disease	I-disease
and	O	O
phenytoin	B-disease	B-disease
sodium	I-disease	I-disease
have	O	O
equivalent	O	O
anticonvulsant	O	O
activity	O	O
against	O	O
seizures	O	O
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
in	O	O
mice	O	O
following	O	O
i	O	O
.	O	O
p	O	O
.	O	O
,	O	O
oral	O	O
,	O	O
or	O	O
i	O	O
.	O	O
v	O	O
.	O	O
administration	O	O
.	O	O
Patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
methamphetamine	B-disease	B-disease
based	O	O
on	O	O
DSM	O	O
-	O	O
IV	O	O
were	O	O
interviewed	O	O
using	O	O
the	O	O
Mini	O	O
International	O	O
Neuropsychiatric	O	O
Interview	O	O
(	O	O
M	O	O
.	O	O
I	O	O
.	O	O
N	O	O
.	O	O
I	O	O
.	O	O
)	O	O
for	O	O
methamphetamine	B-disease	B-disease
-	O	O
induced	O	O
psychosis	O	O
and	O	O
other	O	O
Axis	O	O
I	O	O
psychiatric	O	O
disorders	O	O
.	O	O
Cocaine	B-disease	B-disease
induced	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
heart	O	O
rate	O	O
,	O	O
LV	O	O
dP	O	O
/	O	O
dt	O	O
(	O	O
positive	O	O
or	O	O
negative	O	O
)	O	O
,	O	O
or	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
,	O	O
but	O	O
it	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
systolic	O	O
and	O	O
mean	O	O
arterial	O	O
pressures	O	O
,	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
,	O	O
and	O	O
LV	O	O
end	O	O
-	O	O
systolic	O	O
volume	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
decrease	O	O
in	O	O
LV	O	O
ejection	O	O
fraction	O	O
.	O	O
Serum	O	O
blood	O	O
urea	B-disease	B-disease
and	O	O
creatinine	B-disease	B-disease
concentrations	O	O
increased	O	O
significantly	O	O
in	O	O
rats	O	O
given	O	O
an	O	O
iv	O	O
infusion	O	O
of	O	O
D	B-disease	B-disease
-	I-disease	I-disease
AmB	I-disease	I-disease
3	O	O
mg	O	O
/	O	O
kg	O	O
but	O	O
not	O	O
in	O	O
those	O	O
given	O	O
the	O	O
same	O	O
dose	O	O
of	O	O
NS	O	B-disease
-	O	I-disease
718	O	I-disease
.	O	O
For	O	O
patients	O	O
with	O	O
bilateral	O	O
abductor	O	O
paralysis	O	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
paralytic	O	O
Botox	B-disease	B-disease
dose	O	O
,	O	O
prior	O	O
Botox	B-disease	B-disease
dose	O	O
,	O	O
and	O	O
course	O	O
following	O	O
paralysis	O	O
were	O	O
noted	O	O
.	O	O
Antirifampicin	O	O
antibodies	O	O
in	O	O
acute	O	O
rifampicin	B-disease	B-disease
-	O	O
associated	O	O
renal	O	O
failure	O	O
.	O	O
High	O	O
-	O	O
dose	O	O
intravenous	O	O
melphalan	B-disease	B-disease
followed	O	O
by	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
transplant	O	O
(	O	O
PBSCT	O	O
)	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
most	O	O
promising	O	O
therapy	O	O
,	O	O
but	O	O
treatment	O	O
mortality	O	O
can	O	O
be	O	O
high	O	O
.	O	O
Selectivity	O	O
for	O	O
the	O	O
cerebrovascular	O	O
bed	O	O
makes	O	O
nimodipine	B-disease	B-disease
potentially	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
subarachnoid	O	O
hemorrhage	O	O
,	O	O
migraine	O	O
headache	O	O
,	O	O
dementia	O	O
,	O	O
and	O	O
stroke	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
both	O	O
SOD	O	B-disease
and	O	O
DMTU	B-disease	B-disease
have	O	O
protective	O	O
effects	O	O
on	O	O
GM	B-disease	O
-	O	O
mediated	O	O
nephropathy	O	O
,	O	O
2	O	O
)	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
differ	O	O
for	O	O
SOD	O	B-disease
and	O	O
DMTU	B-disease	B-disease
,	O	O
and	O	O
3	O	O
)	O	O
superoxide	B-disease	B-disease
anions	O	I-disease
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
GM	B-disease	O
-	O	O
induced	O	O
renal	O	O
vasoconstriction	O	O
.	O	O
He	O	O
had	O	O
used	O	O
heroin	B-disease	B-disease
since	O	O
age	O	O
20	O	O
,	O	O
and	O	O
had	O	O
used	O	O
150	O	B-disease
mg	O	I-disease
methadone	B-disease	I-disease
daily	O	O
for	O	O
6	O	O
months	O	O
.	O	O
Adenosine	B-disease	B-disease
triphosphate	I-disease	I-disease
(	O	O
ATP	B-disease	O
)	O	O
and	O	O
sodium	B-disease	B-disease
nitroprusside	I-disease	I-disease
(	O	O
SNP	B-disease	O
)	O	O
are	O	O
administered	O	O
to	O	O
patients	O	O
to	O	O
induce	O	O
and	O	O
control	O	O
hypotension	O	O
during	O	O
anesthesia	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
was	O	O
on	O	O
a	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
valproate	B-disease	B-disease
due	O	O
to	O	O
epilepsy	O	O
and	O	O
revealed	O	O
impaired	O	O
consciousness	O	O
with	O	O
hyperammonemia	O	B-disease
12	O	O
days	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O
OBJECTIVE	O	O
:	O	O
We	O	O
describe	O	O
the	O	O
unique	O	O
CT	O	O
features	O	O
of	O	O
ureteric	O	O
calculi	O	O
in	O	O
six	O	O
HIV	O	O
-	O	O
infected	O	O
patients	O	O
receiving	O	O
indinavir	B-disease	B-disease
,	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
HIV	O	O
protease	O	O
inhibitor	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
urolithiasis	O	O
.	O	O
Acute	O	O
renal	O	O
failure	O	O
due	O	O
to	O	O
rifampicin	B-disease	B-disease
.	O	O
Centrally	O	O
mediated	O	O
cardiovascular	O	O
effects	O	O
of	O	O
intracisternal	O	O
application	O	O
of	O	O
carbachol	B-disease	B-disease
in	O	O
anesthetized	O	O
rats	O	O
.	O	O
Hippocampal	O	O
deficits	O	O
were	O	O
mapped	O	O
and	O	O
correlated	O	O
with	O	O
memory	O	O
performance	O	O
on	O	O
a	O	O
word	O	O
-	O	O
recall	O	O
test	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O
Morphine	B-disease	B-disease
-	O	O
induced	O	O
seizures	O	O
in	O	O
newborn	O	O
infants	O	O
.	O	O
Thirty	O	O
-	O	O
six	O	O
rats	O	O
bearing	O	O
breast	O	O
tumors	O	O
induced	O	O
chemically	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
hydroxytyrosol	B-disease	B-disease
(	O	O
0	O	O
.	O	O
5mg	O	O
/	O	O
kg	O	O
,	O	O
5days	O	O
/	O	O
week	O	O
)	O	O
,	O	O
doxorubicin	B-disease	B-disease
(	O	O
1mg	O	O
/	O	O
kg	O	O
/	O	O
week	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B-disease	B-disease
plus	O	O
hydroxytyrosol	B-disease	B-disease
.	O	O
CONCLUSION	O	O
:	O	O
This	O	O
report	O	O
describes	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
with	O	O
LACNP	O	B-disease
that	O	O
developed	O	O
after	O	O
a	O	O
steroid	B-disease	B-disease
injection	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lateral	O	O
epicondylitis	O	O
.	O	O
In	O	O
both	O	O
groups	O	O
postprocedural	O	O
(	O	O
48	O	O
h	O	O
)	O	O
serum	O	O
creatinine	B-disease	B-disease
was	O	O
measured	O	O
.	O	O
Vincristine	B-disease	B-disease
was	O	O
accidentally	O	O
given	O	O
intrathecally	O	O
to	O	O
a	O	O
child	O	O
with	O	O
leukaemia	O	O
,	O	O
producing	O	O
sensory	O	O
and	O	O
motor	O	O
dysfunction	O	O
followed	O	O
by	O	O
encephalopathy	O	O
and	O	O
death	O	O
.	O	O
The	O	O
changes	O	O
in	O	O
renal	O	O
prostaglandin	B-disease	O
synthesis	O	O
were	O	O
accompanied	O	O
by	O	O
evidence	O	O
of	O	O
renal	O	O
damage	O	O
in	O	O
aspirin	B-disease	B-disease
-	O	O
treated	O	O
jj	O	O
but	O	O
not	O	O
jJ	O	O
rats	O	O
as	O	O
evidenced	O	O
by	O	O
:	O	O
increased	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
hematuria	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
01	O	O
)	O	O
;	O	O
increased	O	O
serum	O	O
creatinine	B-disease	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
;	O	O
and	O	O
increase	O	O
in	O	O
outer	O	O
medullary	O	O
histopathologic	O	O
lesions	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O
005	O	O
compared	O	O
to	O	O
either	O	O
sham	O	O
-	O	O
treated	O	O
jj	O	O
or	O	O
aspirin	B-disease	B-disease
-	O	O
treated	O	O
jJ	O	O
)	O	O
.	O	O
Adverse	O	O
reactions	O	O
to	O	O
drugs	O	B-disease
are	O	O
well	O	O
recognized	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	O
urticaria	O	B-disease
,	O	O
and	O	O
angio	O	B-disease
-	O	I-disease
oedema	O	I-disease
.	O	O
Hepatocellular	O	O
carcinoma	O	O
in	O	O
Fanconi	O	O
'	O	O
s	O	O
anemia	O	O
treated	O	O
with	O	O
androgen	B-disease	B-disease
and	O	O
corticosteroid	B-disease	B-disease
.	O	O
Nociceptin	B-disease	B-disease
/	O	O
orphanin	B-disease	B-disease
FQ	I-disease	I-disease
and	O	O
nocistatin	B-disease	B-disease
on	O	O
learning	O	O
and	O	O
memory	O	O
impairment	O	O
induced	O	O
by	O	O
scopolamine	B-disease	B-disease
in	O	O
mice	O	O
.	O	O
Reactive	O	B-disease
oxygen	B-disease	I-disease
species	O	I-disease
particularly	O	O
affect	O	O
the	O	O
cardiac	O	O
myocytes	O	O
because	O	O
these	O	O
cells	O	O
seem	O	O
to	O	O
have	O	O
a	O	O
relatively	O	O
poor	O	O
antioxidant	O	O
defense	O	O
system	O	O
.	O	O
A	O	O
group	O	O
of	O	O
doctors	O	O
in	O	O
Boston	O	O
warn	O	O
that	O	O
the	O	O
protease	O	B-disease
inhibitor	O	I-disease
Viracept	B-disease	B-disease
may	O	O
cause	O	O
an	O	O
irregular	O	O
heart	O	O
beat	O	O
,	O	O
known	O	O
as	O	O
bradycardia	O	B-disease
,	O	O
in	O	O
people	O	O
with	O	O
HIV	O	B-disease
.	O	O
A	O	O
higher	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
leukocyturia	O	O
was	O	O
found	O	O
in	O	O
children	O	O
with	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
>	O	O
19	O	B-disease
mg	O	I-disease
/	O	I-disease
L	O	I-disease
x	O	I-disease
h	O	I-disease
or	O	O
a	O	O
peak	O	O
serum	O	O
level	O	O
of	O	O
indinavir	B-disease	B-disease
>	O	O
12	O	B-disease
mg	O	I-disease
/	O	I-disease
L	O	I-disease
.	O	O
Intravenous	O	O
propranolol	B-disease	B-disease
after	O	O
PPA	B-disease	B-disease
also	O	O
decreased	O	O
blood	O	O
pressure	O	O
.	O	O
RESULTS	O	O
:	O	O
There	O	O
were	O	O
no	O	O
group	O	O
differences	O	O
in	O	O
psychopathology	O	O
or	O	O
""""	O	O
eyes	O	O
task	O	O
""""	O	O
performance	O	O
,	O	O
but	O	O
the	O	O
RC	O	B-disease
group	O	O
,	O	O
who	O	O
otherwise	O	O
had	O	O
similar	O	O
illicit	O	O
substance	O	O
use	O	O
histories	O	O
to	O	O
the	O	O
OC	O	B-disease
group	O	O
,	O	O
exhibited	O	O
impaired	O	O
fear	O	O
recognition	O	O
accuracy	O	O
compared	O	O
to	O	O
the	O	O
OC	O	B-disease
and	O	O
CN	O	B-disease
groups	O	O
.	O	O
Bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
L6	O	O
-	O	O
S1	O	O
DRG	O	O
labeled	O	O
by	O	O
Fluorogold	O	B-disease
(	O	O
40	O	O
microliters	O	O
)	O	O
injected	O	O
into	O	O
the	O	O
bladder	O	O
wall	O	O
did	O	O
not	O	O
exhibit	O	O
NOS	O	O
-	O	O
IR	O	O
in	O	O
control	O	O
animals	O	O
;	O	O
however	O	O
,	O	O
following	O	O
chronic	O	O
CYP	B-disease	B-disease
administration	O	O
,	O	O
a	O	O
significant	O	O
percentage	O	O
of	O	O
bladder	O	O
afferent	O	O
neurons	O	O
were	O	O
NOS	O	O
-	O	O
IR	O	O
:	O	O
L6	O	O
(	O	O
19	O	O
.	O	O
8	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O
6	O	O
%	O	O
)	O	O
and	O	O
S1	O	O
(	O	O
25	O	O
.	O	O
3	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O
Thirty	O	O
-	O	O
five	O	O
patients	O	O
(	O	O
13	O	O
.	O	O
4	O	O
%	O	O
)	O	O
had	O	O
visual	O	O
field	O	O
abnormalities	O	O
,	O	O
which	O	O
were	O	O
attributed	O	O
to	O	O
hydroxychloroquine	B-disease	B-disease
treatment	O	O
in	O	O
4	O	O
patients	O	O
(	O	O
1	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O
Until	O	O
then	O	O
digoxin	B-disease	B-disease
should	O	O
be	O	O
considered	O	O
a	O	O
third	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O
The	O	O
randomized	O	O
Aza	B-disease	B-disease
patients	O	O
had	O	O
more	O	O
overall	O	O
infections	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
more	O	O
nonviral	O	O
infections	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O
02	O	O
)	O	O
than	O	O
the	O	O
randomized	O	O
cyclosporine	B-disease	B-disease
patients	O	O
.	O	O
Pretreatment	O	O
of	O	O
rats	O	O
with	O	O
sodium	B-disease	B-disease
salicylate	I-disease	I-disease
,	O	O
ED50	O	O
103	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
60	O	O
-	O	O
174	O	O
)	O	O
,	O	O
and	O	O
phenylbutazone	B-disease	B-disease
,	O	O
59	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
50	O	O
-	O	O
70	O	O
)	O	O
converted	O	O
the	O	O
non	O	O
-	O	O
convulsant	O	O
dose	O	O
of	O	O
pilocarpine	B-disease	B-disease
,	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
to	O	O
a	O	O
convulsant	O	O
one	O	O
.	O	O
In	O	O
contrast	O	O
reports	O	O
indicate	O	O
that	O	O
hippocampal	O	O
dependent	O	O
neurogenesis	O	O
and	O	O
cognition	O	O
are	O	O
enhanced	O	O
by	O	O
the	O	O
SSRI	B-disease	B-disease
antidepressant	O	O
Fluoxetine	B-disease	B-disease
.	O	O
Antibodies	O	O
against	O	O
the	O	O
astroglia	O	O
-	O	O
specific	O	O
cytoskeletal	O	O
protein	O	O
,	O	O
glial	O	B-disease
fibrillary	O	I-disease
acidic	O	I-disease
protein	O	I-disease
(	O	O
GFAP	O	O
)	O	O
,	O	O
and	O	O
against	O	O
the	O	O
glial	O	O
calcium	B-disease	O
-	O	O
binding	O	O
protein	O	O
,	O	O
S	O	B-disease
-	O	I-disease
100	O	I-disease
protein	O	I-disease
,	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
status	O	O
of	O	O
astrocytes	O	O
.	O	O
STZ	B-disease	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
level	O	O
of	O	O
ROS	O	B-disease
,	O	O
nitrite	B-disease	B-disease
,	O	O
Ca	B-disease	B-disease
(	O	I-disease
2	O	I-disease
+	O	I-disease
)	O	I-disease
and	O	O
reduced	O	O
the	O	O
mitochondrial	O	O
activity	O	O
in	O	O
synaptosomal	O	O
preparation	O	O
illustrating	O	O
free	O	O
radical	O	O
generation	O	O
and	O	O
excitotoxicity	O	O
.	O	O
The	O	O
incidence	O	O
of	O	O
cardiac	O	O
events	O	O
with	O	O
VNR	B-disease	B-disease
was	O	O
1	O	O
.	O	O
19	O	O
%	O	O
[	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
(	O	O
0	O	O
.	O	O
75	O	O
;	O	O
1	O	O
.	O	O
67	O	O
)	O	O
]	O	O
.	O	O
Paclitaxel	B-disease	B-disease
,	O	O
5	B-disease	B-disease
-	I-disease	I-disease
fluorouracil	I-disease	I-disease
,	O	O
and	O	O
folinic	B-disease	B-disease
acid	I-disease	I-disease
in	O	O
metastatic	O	O
breast	O	O
cancer	O	O
:	O	O
BRE	O	O
-	O	O
26	O	O
,	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
.	O	O
Genetic	O	O
separation	O	O
of	O	O
tumor	O	O
growth	O	O
and	O	O
hemorrhagic	O	O
phenotypes	O	O
in	O	O
an	O	O
estrogen	B-disease	B-disease
-	O	O
induced	O	O
tumor	O	O
.	O	O
We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
who	O	O
developed	O	O
acute	O	O
cytolytic	O	O
hepatitis	O	O
due	O	O
to	O	O
meloxicam	B-disease	B-disease
.	O	O
We	O	O
conclude	O	O
that	O	O
:	O	O
1	O	O
)	O	O
administration	O	O
of	O	O
rhIGF	O	B-disease
-	O	I-disease
I	O	I-disease
improves	O	O
growth	O	O
and	O	O
GFR	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B-disease	O
nephropathy	O	O
and	O	O
2	O	O
)	O	O
unlike	O	O
rhGH	O	B-disease
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
rhIGF	O	B-disease
-	O	I-disease
I	O	I-disease
does	O	O
not	O	O
worsen	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
this	O	O
disease	O	O
model	O	O
.	O	O
DATA	O	O
SYNTHESIS	O	O
:	O	O
New	O	O
evidence	O	O
from	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
RCT	O	O
,	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
meta	O	O
-	O	O
analysis	O	O
,	O	O
and	O	O
2	O	O
fair	O	O
-	O	O
quality	O	O
subanalyses	O	O
of	O	O
RCTs	O	O
demonstrates	O	O
that	O	O
aspirin	B-disease	B-disease
use	O	O
reduces	O	O
the	O	O
number	O	O
of	O	O
CVD	O	O
events	O	O
in	O	O
patients	O	O
without	O	O
known	O	O
CVD	O	O
.	O	O
She	O	O
received	O	O
a	O	O
second	O	O
cycle	O	O
of	O	O
nelarabine	B-disease	B-disease
without	O	O
additional	O	O
IT	O	O
prophylaxis	O	O
one	O	O
month	O	O
later	O	O
.	O	O
YMDD	O	B-disease
motif	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
despite	O	O
the	O	O
liver	O	O
enzyme	O	O
levels	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
HBeAg	B-disease	B-disease
or	O	O
anti	O	B-disease
-	O	I-disease
HBe	O	I-disease
.	O	O
Eight	O	O
animals	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
sedentary	O	O
control	O	O
(	O	O
SC	O	B-disease
)	O	O
group	O	O
which	O	O
remained	O	O
sedentary	O	O
throughout	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O
We	O	O
report	O	O
three	O	O
cases	O	O
of	O	O
severe	O	O
hypoxaemia	O	O
after	O	O
ibuprofen	B-disease	B-disease
administration	O	O
during	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
of	O	O
prophylactic	O	O
treatment	O	O
of	O	O
patent	O	O
ductus	O	O
arteriosus	O	O
with	O	O
ibuprofen	B-disease	B-disease
in	O	O
premature	O	O
infants	O	O
born	O	O
at	O	O
less	O	O
than	O	O
28	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O
Concomitant	O	O
use	O	O
of	O	O
oral	O	O
prednisone	B-disease	B-disease
and	O	O
topical	O	O
beclomethasone	B-disease	B-disease
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
hoarseness	O	O
or	O	O
candidiasis	O	O
.	O	O
He	O	O
then	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
feeling	O	O
quite	O	O
ill	O	O
and	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
blood	B-disease	B-disease
urea	I-disease	I-disease
nitrogen	I-disease	I-disease
(	O	I-disease
BUN	B-disease	I-disease
)	O	I-disease
concentration	O	O
of	O	O
of	O	O
147	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
creatinine	B-disease	B-disease
of	O	O
15	O	O
.	O	O
3	O	O
mg	O	O
/	O	O
dl	O	O
and	O	O
serum	O	B-disease
potassium	B-disease	I-disease
of	O	O
8	O	O
.	O	O
7	O	O
mEq	O	O
/	O	O
l	O	O
.	O	O
In	O	O
this	O	O
investigation	O	O
the	O	O
behavioural	O	O
effects	O	O
of	O	O
chronic	O	O
(	O	O
two	O	O
week	O	O
)	O	O
treatment	O	O
with	O	O
5	B-disease	B-disease
-	I-disease	I-disease
FU	I-disease	I-disease
and	O	O
(	O	O
three	O	O
weeks	O	O
)	O	O
with	O	O
Fluoxetine	B-disease	B-disease
either	O	O
separately	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
5	B-disease	B-disease
-	I-disease	I-disease
FU	I-disease	I-disease
were	O	O
tested	O	O
on	O	O
adult	O	O
Lister	O	O
hooded	O	O
rats	O	O
.	O	O
The	O	O
restimulation	O	O
of	O	O
this	O	O
area	O	O
with	O	O
N	B-disease	B-disease
-	I-disease	I-disease
methyl	I-disease	I-disease
-	I-disease	I-disease
D	I-disease	I-disease
-	I-disease	I-disease
aspartic	I-disease	I-disease
acid	I-disease	I-disease
15	O	O
days	O	O
postlesion	O	O
failed	O	O
to	O	O
produce	O	O
a	O	O
pressor	O	O
response	O	O
.	O	O
By	O	O
combining	O	O
information	O	O
from	O	O
the	O	O
patient	O	O
history	O	O
,	O	O
the	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
radiologic	O	O
and	O	O
laboratory	O	O
studies	O	O
,	O	O
the	O	O
critical	O	O
care	O	O
team	O	O
demonstrated	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
self	O	O
-	O	O
treating	O	O
his	O	O
lithium	B-disease	B-disease
-	O	O
induced	O	O
nephrogenic	O	O
DI	O	O
and	O	O
developed	O	O
neurogenic	O	O
DI	O	O
secondary	O	O
to	O	O
brain	O	O
trauma	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
AChE	O	B-disease
activity	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
,	O	O
cerebellum	O	O
and	O	O
hippocampus	O	O
.	O	O
This	O	O
study	O	O
shows	O	O
that	O	O
busulfan	B-disease	B-disease
neurotoxicity	O	O
is	O	O
dose	O	O
-	O	O
dependent	O	O
in	O	O
children	O	O
and	O	O
efficiently	O	O
prevented	O	O
by	O	O
clonazepam	B-disease	B-disease
.	O	O
The	O	O
authors	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
56	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
chronic	O	O
,	O	O
severe	O	O
heart	O	O
failure	O	O
secondary	O	O
to	O	O
dilated	O	O
cardiomyopathy	O	O
and	O	O
absence	O	O
of	O	O
significant	O	O
ventricular	O	O
arrhythmias	O	O
who	O	O
developed	O	O
QT	O	O
prolongation	O	O
and	O	O
torsade	O	O
de	O	O
pointes	O	O
ventricular	O	O
tachycardia	O	O
during	O	O
one	O	O
cycle	O	O
of	O	O
intermittent	O	O
low	O	O
dose	O	O
(	O	O
2	O	O
.	O	O
5	O	O
mcg	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
)	O	O
dobutamine	B-disease	B-disease
.	O	O
Dehydrated	O	O
rats	O	O
regularly	O	O
develop	O	O
acute	O	O
renal	O	O
failure	O	O
following	O	O
single	O	O
injection	O	O
of	O	O
aminoglycoside	B-disease	B-disease
antibiotics	O	I-disease
combined	O	O
with	O	O
dextran	O	B-disease
or	O	O
of	O	O
antibiotics	O	B-disease
only	O	O
.	O	O
Myopathy	O	O
due	O	O
to	O	O
lack	O	O
of	O	O
vitamin	B-disease	B-disease
E	I-disease	I-disease
and	O	O
myopathy	O	O
induced	O	O
by	O	O
certain	O	O
viruses	O	O
have	O	O
much	O	O
in	O	O
common	O	O
anatomically	O	O
and	O	O
pathologically	O	O
with	O	O
the	O	O
human	O	O
form	O	O
.	O	O
This	O	O
unexpected	O	O
complication	O	O
indicates	O	O
the	O	O
need	O	O
for	O	O
further	O	O
toxicology	O	O
research	O	O
on	O	O
IT	O	B-disease
-	O	I-disease
TSPA	B-disease	I-disease
.	O	O
This	O	O
was	O	O
significantly	O	O
different	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O
02	O	O
)	O	O
from	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
previously	O	O
defined	O	O
in	O	O
children	O	O
receiving	O	O
a	O	O
16	O	O
-	O	O
mg	O	O
/	O	O
kg	O	O
total	O	O
dose	O	O
of	O	O
busulfan	B-disease	B-disease
.	O	O
Moderate	O	O
to	O	O
high	O	O
dose	O	O
corticosteroid	B-disease	B-disease
use	O	O
is	O	O
recognized	O	O
as	O	O
a	O	O
major	O	O
risk	O	O
factor	O	O
for	O	O
SRC	O	O
.	O	O
Therefore	O	O
,	O	O
the	O	O
BNPP	B-disease	B-disease
-	O	O
induced	O	O
reduction	O	O
in	O	O
APAP	B-disease	B-disease
-	O	O
induced	O	O
nephrotoxicity	O	O
appears	O	O
to	O	O
be	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
APAP	B-disease	B-disease
deacetylation	O	O
.	O	O
Troponin	O	B-disease
appears	O	O
to	O	O
have	O	O
an	O	O
equivalent	O	O
diagnostic	O	O
accuracy	O	O
compared	O	O
with	O	O
CK	O	B-disease
-	O	I-disease
MB	O	I-disease
for	O	O
diagnosing	O	O
necrosis	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-disease	B-disease
-	O	O
associated	O	O
chest	O	O
pain	O	O
and	O	O
suspected	O	O
MI	O	O
.	O	O
We	O	O
report	O	O
on	O	O
a	O	O
14	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
developed	O	O
acute	O	O
renal	O	O
failure	O	O
2	O	O
weeks	O	O
after	O	O
aortic	O	B-disease
valve	O	I-disease
surgery	O	O
.	O	O
CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
suggest	O	O
that	O	O
fluocinolone	B-disease	B-disease
acetonide	I-disease	I-disease
implant	O	O
(	O	O
0	O	B-disease
.	O	I-disease
59	O	I-disease
mg	O	I-disease
)	O	O
helps	O	O
to	O	O
control	O	O
inflammation	O	O
in	O	O
otherwise	O	O
treatment	O	O
-	O	O
refractory	O	O
cases	O	O
of	O	O
birdshot	O	O
retinochoroidopathy	O	O
.	O	O
RESULTS	O	O
:	O	O
Postprocedural	O	O
creatinine	B-disease	B-disease
level	O	O
decreased	O	O
nonsignificantly	O	O
in	O	O
the	O	O
PTRA	O	O
group	O	O
(	O	O
1	O	O
.	O	O
46	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
8	O	O
vs	O	O
.	O	O
1	O	O
.	O	O
34	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
5	O	O
mg	O	B-disease
/	O	I-disease
dl	O	I-disease
,	O	O
P	O	O
=	O	O
NS	O	O
)	O	O
and	O	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
PCI	O	O
group	O	O
(	O	O
1	O	O
.	O	O
44	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
6	O	O
vs	O	O
.	O	O
1	O	O
.	O	O
57	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
7	O	O
mg	O	B-disease
/	O	I-disease
dl	O	I-disease
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O
HOMER1	O	B-disease
is	O	O
a	O	O
protein	O	O
with	O	O
pivotal	O	O
function	O	O
in	O	O
glutamate	B-disease	B-disease
transmission	O	O
,	O	O
which	O	O
has	O	O
been	O	O
related	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
these	O	O
complications	O	O
.	O	O
A	O	O
comparison	O	O
of	O	O
severe	O	O
hemodynamic	O	O
disturbances	O	O
between	O	O
dexmedetomidine	B-disease	B-disease
and	O	O
propofol	B-disease	B-disease
for	O	O
sedation	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
.	O	O
The	O	O
compound	O	O
manifests	O	O
antiarrhythmic	O	O
activity	O	O
in	O	O
all	O	O
models	O	O
of	O	O
experimental	O	O
arrhythmia	O	O
used	O	O
,	O	O
causing	O	O
greatest	O	O
inhibition	O	O
on	O	O
the	O	O
arrhythmia	O	O
induced	O	O
by	O	O
chloroform	B-disease	B-disease
-	O	O
adrenaline	B-disease	B-disease
(	O	O
in	O	O
90	O	O
per	O	O
cent	O	O
)	O	O
and	O	O
with	O	O
BaCl2	B-disease	B-disease
(	O	O
in	O	O
84	O	O
per	O	O
cent	O	O
)	O	O
.	O	O
1	O	O
.	O	O
Herein	O	O
,	O	O
we	O	O
investigate	O	O
whether	O	O
doxorubicin	B-disease	B-disease
-	O	O
associated	O	O
chronic	O	O
cardiac	O	O
toxicity	O	O
can	O	O
be	O	O
ameliorated	O	O
with	O	O
the	O	O
antioxidant	O	O
hydroxytyrosol	B-disease	B-disease
in	O	O
rats	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O
